New Monoclonal Antibody for Epithelial Cell Research
In March, Beckman Coulter introduced the new IOTest® CD136 (RON)-PE conjugated monoclonal antibody for the identification of a receptor protein kinase potentially involved in tumor development and growth.
The CD136 antigen is the product of the recepteur d’origine nantais (RON) gene and is mainly expressed on cells of epithelial origin. The RON receptor belongs to a group of kinases that play an important regulatory role in normal tissue and can also be involved in cellular disorganization and alteration when overexpressed or mutated.
The company’s new CD136 (RON) antibody will be valuable in a range of basic and clinical research and is used in a number of recent and current cancer studies. It will also be useful in pharmaceutical research on therapies designed to block the tumorigenic process.
The performulated, standardized IOTest CD136 (RON)-PE monoclonal antibody is provided in 100-test vials and is the only directly conjugated monoclonal antibody on the market. It can be used to assess RON expression on both normal and abnormal epithelial cells, recognizing proRON and RON, as well as the three known RON variants. CD136 (RON)-PE is currently approved for research use only and not for use in diagnostic procedures.
“This antigen marker is very important for the study of epithelial tumors,” commented Michel Pagniez, Cellular Analysis Product Manager for Beckman Coulter. “The successful blocking of this kinase could result in efficient cancer therapies.” |
